(Circulation. 1997;95:557-559.)
© 1997 American Heart Association, Inc.
Articles |
Oxidative Stress Produced by Angiotensin Too
Implications for Hypertension and Vascular Injury
the Department of Internal Medicine, Division of Cardiovascular Diseases, University of Iowa Hospitals and Clinics, Iowa City.
Correspondence to Helgi J. Oskarsson, MD, Assistant Professor, Department of Internal Medicine, Division of Cardiovascular Diseases, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA 52242. E-mail Helgi-Oskarsson@uiowa.edu.
Key Words: Editorials • endothelium-derived factors • hypertension • free radicals
 |
Introduction |
|---|
 Top Introduction Evidence That Angiotensin II...Importance of the ResultsImplications of Angiotensin...Relevance to the Clinical...References |
|---|
Since the landmark study on renovascular hypertension by Goldblatt et al in 1934,1 it has become clear that the RAS plays a major role in hypertension and other cardiovascular disorders. Although the mechanism for RAS-induced hypertension is generally attributed to vasoconstrictor effects of angiotensin II and the salt- and water-retaining effects of aldosterone, a study by Bech Laursen et al in this issue of Circulation2 suggests an additional mechanism.
|
Evidence That Angiotensin II Causes Hypertension via Production of Superoxide Radical |
|---|
|
TopIntroductionEvidence That Angiotensin II...Importance of the ResultsImplications of Angiotensin...Relevance to the Clinical...References |
|---|
The study by Bech Laursen et al, coupled with their previous findings,3 suggests that angiotensin II–induced hypertension in rats is associated with a large increase in vascular production of superoxide radical, which is accompanied by impairment of EDNO-dependent vasodilation. This was not observed in rats made equally hypertensive by norepinephrine infusion.
The authors also observed that chronic infusion of liposome-encapsulated SOD increased conduit vessel SOD activity by 30%. This rather modest increase in SOD activity was nevertheless associated with normalization of superoxide release in the aorta from rats made hypertensive by angiotensin II, with restoration of normal EDNO-dependent vasorelaxation.
In addition, the authors showed that the development of hypertension in response to long-term infusion of angiotensin II was significantly inhibited by coadministration of liposome-encapsulated SOD, whereas the same treatment had no effect on hypertension induced by infusion of norepinephrine. Furthermore, rats with angiotensin II–induced hypertension that received liposome-encapsulated SOD showed a significantly greater reduction in mean arterial blood pressure in response to the endothelium-dependent vasodilator acetylcholine than did rats that were not treated with SOD. This suggests that SOD supplementation improves endothelial function not only in conduit arteries but also in resistance vessels.
Bech Laursen et al conclude that a substantial portion of angiotensin II–mediated hypertension is produced by an increase in endogenous superoxide production by vessels, leading to degradation of EDNO.
|
Importance of the Results |
|---|
|
TopIntroductionEvidence That Angiotensin II...Importance of the ResultsImplications of Angiotensin...Relevance to the Clinical...References |
|---|
The data provided in the present study of Bech Laursen et al are important because they provide evidence for an underappreciated mechanism by which angiotensin II can produce hypertension. Nevertheless, it should be noted that although liposome-encapsulated SOD therapy normalized superoxide production by vessels and was associated with significant reduction in arterial pressure in rats treated with angiotensin II, their blood pressure remained elevated. This persistent elevation of pressure suggests additional mechanisms for angiotensin II–mediated hypertension, which may include direct vasoconstrictor effects of angiotensin II, and angiotensin II–mediated increase in release of endothelin,4 vasoconstrictor prostanoids,5 and lipoxygenase products.6
Perhaps of even greater importance is the general implication of oxidative stress induced by angiotensin II, through which the RAS not only influences blood pressure but theoretically may affect a variety of other important biological phenomena that are relevant to vascular pathophysiology.
|
Implications of Angiotensin II–Mediated Oxidative Stress |
|---|
|
TopIntroductionEvidence That Angiotensin II...Importance of the ResultsImplications of Angiotensin...Relevance to the Clinical...References |
|---|
By interfering with the bioavailability of EDNO,7 increased superoxide production potentially has many important consequences related to the numerous effects of EDNO within the vessel wall and lumen. EDNO inhibits platelet adhesion and aggregation, decreases leukocyte adherence to endothelium, produces vasodilation, and inhibits smooth muscle cell proliferation and production of extracellular matrix. Furthermore, the reaction of NO with superoxide radical leads to formation of peroxynitrite, a reactive oxygen species that can initiate lipid peroxidation and may be toxic to cells.8 Peroxynitrite may also play a role in oxidation of lipoproteins within the vessel wall, an important step in the development of atherosclerosis.9
In addition, increased production and release of reactive oxygen species within the vessel wall may directly produce vasoconstriction,10 affect platelet activation,11 and influence intracoronary thrombosis.12 Furthermore, angiotensin II enhances the release of plasminogen activator inhibitor,13 perhaps in part by enhanced oxidative stress.14
Reactive oxygen species may also represent an important signal transduction pathway inside cells.15 They have been shown to participate in the expression of cell-adhesion molecules on endothelial cells.16 17 They also may play a role in the activation of several early-response elements such as c-fos and c-jun, which are known to be stimulated by angiotensin II, in part via reactive oxygen intermediates,18 which can lead to cell proliferation or hypertrophy, depending on interaction with other growth factors.
Thus, by increasing production of free radicals within the vessel wall, angiotensin II, at least theoretically, can influence processes that affect vascular tone, vascular remodeling, development of atherosclerosis and neointimal proliferation, and intravascular thrombosis. This mechanism could contribute to the observed association among various genotypes that influence RAS activity and appear to affect the risk of cardiovascular complications such as atherosclerosis, myocardial infarction, and stroke,19 20 21 22 regardless of whether the patients are hypertensive. Similarly, this mechanism could provide a rational for the provocative hypothesis that elevation of renin levels in patients with hypertension may be a risk factor for cardiovascular events, a hypothesis that is supported by some23 but not all studies.24
Taken together, these observations support the notion that activity of the RAS has important implications beyond its well-recognized role in the pathophysiology of hypertension.
|
Relevance to the Clinical Effects of ACE Inhibitors |
|---|
|
TopIntroductionEvidence That Angiotensin II...Importance of the ResultsImplications of Angiotensin...Relevance to the Clinical...References |
|---|
ACE inhibitors block the conversion of angiotensin I to angiotensin II and therefore presumably decrease oxidative stress induced by angiotensin II. This may explain some of the benefits observed in clinical trials with ACE-inhibitor therapy in patients with cardiovascular diseases. For example, ACE inhibitors have been reported to improve endothelium-dependent coronary vasodilatation in patients with atherosclerosis.25 The data presented by Bech Laursen et al2 suggest that if endogenous free radical production in vessels can be inhibited and degradation of NO reduced, EDNO-dependent vasodilation is improved. Therefore, one mechanism by which ACE inhibitors may improve endothelium-dependent vasodilation is by blocking angiotensin II–mediated production of superoxide radical.26 Furthermore, ACE inhibitors inhibit degradation of bradykinin and other kinins. Because bradykinin releases both NO and prostacyclin from endothelial cells, ACE inhibition may both increase release and decrease superoxide-mediated degradation of these important vasodilators and platelet inhibitors. Perhaps the decreased risk for recurrent ischemic cardiac events in patients after myocardial infarction randomized to ACE-inhibitor therapy in the SAVE27 and the SOLVE28 trials can be explained in part by this mechanism.
Conclusions
In summary, the demonstration of angiotensin II–induced free radical generation in vessels as a mechanism for hypertension and as a potential mechanism by which the RAS influences the pathophysiology of various other cardiovascular disorders is an important contribution to vascular biology. Similarly, in light of evidence that oxidative stress plays a major role in development of cardiovascular disorders, inhibition of this mechanism may contribute to the efficacy of clinical interventions targeted toward the RAS in a variety of cardiovascular diseases.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Footnotes |
|---|
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
|
References |
|---|
|
TopIntroductionEvidence That Angiotensin II...Importance of the ResultsImplications of Angiotensin...Relevance to the Clinical...References |
|---|
1. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension, I: the production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med. 1934;59:347-379.[Abstract]
2.
Bech Laursen J, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II–induced but not catecholamine-induced hypertension. Circulation.. 1997;95:588-593.
3. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.[Medline] [Order article via Infotrieve]
4.
Dohi Y, Hahn AWA, Boulanger CM, Buhler FR, Luscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension. 1992;19:131-137.
5.
Lin L, Mistry M, Stier CT, Nasjletti A. Role of prostanoids in renin-dependent and renin-independent hypertension. Hypertension. 1991;17:517-525.
6.
Stern N, Golub M, Nozawa K, Berger M, Knoll E, Yanagawa N, Natarajan R, Nadler JL, Tuck ML. Selective inhibition of angiotensin II mediated vasoconstriction by lipoxygenase blockade. Am J Physiol. 1989;257:H434-H443.
7. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature. 1986;320:454-456.[Medline] [Order article via Infotrieve]
8.
Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990;87:1620-1624.
9.
White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, Bradley WA, Gianturco SH, Gore J, Freeman BA. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A. 1994;91:1044-1048.
10.
Katusic ZS, Vanhoutte PM. Superoxide anion is an endothelium-derived contracting factor. Am J Physiol. 1989;257:H33-H37.
11. Iuliano L, Pedersen JZ, Pratico D, Rotilio G, Violi F. Role of hydroxyl radicals in the activation of human platelets. Eur J Biochem. 1994;221:695-704.[Medline] [Order article via Infotrieve]
12.
Yao SK, Ober JC, Gonenne A, Clubb FJ, Krishnaswami A, Ferguson JJ, Anderson HV, Gorecki M, Buja LM, Willerson JT. Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries. Circ Res. 1993;73:952-967.
13.
Ridker PM, Gaboury CL, Conlin PR, Seely E, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;87:1969-1973.
14. Ceriello A, Curcio F, Dello RP, Pegoraro I, Stel G, Amstad P, Cerutti P. The defence against free radicals protects endothelial cells from hyperglycaemia-induced plasminogen activator inhibitor 1 over-production. Blood Coagul Fibrinolysis. 1995;6:133-137.[Medline] [Order article via Infotrieve]
15.
Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science. 1995;270:296-299.
16. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92:1866-1874.
17. Fraticelli A, Serrano CV Jr, Bochner BS, Capogrossi MC, Zweier JL. Hydrogen peroxide and superoxide modulate leukocyte adhesion molecule expression and leukocyte endothelial adhesion. Biochim Biophys Acta. 1996;1310:251-259.[Medline] [Order article via Infotrieve]
18.
Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M. Reactive oxygen intermediates mediate angiotensin II-induced c-jun c-fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells. J Biol Chem. 1995;270:22129-22134.
19. Cambien F, Poirier O, Lecerf L. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1993;359:641-644.
20.
Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 1996;94:708-712.
21. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, Arveiler D, Luc G, Kee F, Ducimetiere P, Soubrier F, Cambien F. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet. 1994;344:910-913.[Medline] [Order article via Infotrieve]
22.
Kario K, Kanai N, Saito K, Nago N, Matsuo T, Shimada K. Ischemic stroke and the gene for angiotensin-converting enzyme in Japanese hypertensives. Circulation. 1996;93:1630-1633.
23. Alderman MH, Madhavan SH, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarctions in patients with hypertension. N Engl J Med. 1991;324:1098-1104.[Abstract]
24.
Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med. 1993;329:616-619.
25.
Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996;94:258-265.
26.
Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors: a new trend? Circulation. 1996;94:240-243.
27.
Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, Braunwald E. Effects of captopril on ischemic events after myocardial infarction: results of the Survival And Ventricular Enlargement trial. Circulation. 1994;90:1731-1738.
28. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  B. Somoza, M. C. Gonzalez, J. M. Gonzalez, F. Abderrahim, S. M. Arribas, and M. S. Fernandez-Alfonso Modulatory role of the adventitia on noradrenaline and angiotensin II responses: Role of endothelium and AT2 receptors Cardiovasc Res, February 1, 2005; 65(2): 478 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F. Lopes, K. L. Martin, K. Nashar, J. D. Morrow, T. L. Goodfriend, and B. M. Egan DASH Diet Lowers Blood Pressure and Lipid-Induced Oxidative Stress in Obesity Hypertension, March 1, 2003; 41(3): 422 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, G. D. Fink, S. W. Watts, C. A. Northcott, J. J. Galligan, P. J. Pagano, and A. F. Chen Endothelin-1 Increases Vascular Superoxide via EndothelinA-NADPH Oxidase Pathway in Low-Renin Hypertension Circulation, February 25, 2003; 107(7): 1053 - 1058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Schachinger and A. M. Zeiher Atherogenesis--recent insights into basic mechanisms and their clinical impact Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2055 - 2064. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Prasad, J. P. J. Halcox, M. A. Waclawiw, and A. A. Quyyumi Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1089 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Glantz and W. W. Parmley Even a Little Secondhand Smoke Is Dangerous JAMA, July 25, 2001; 286(4): 462 - 463. [Full Text] [PDF]
|
|
|
|
 |
|
 M.-S. Zhou, A. Adam, and L. Raij Review: Interaction among angiotensin II, nitric oxide and oxidative stress Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S59 - S63. [PDF]
|
|
|
|
|
|
L. O. Lerman, K. A. Nath, M. Rodriguez-Porcel, J. D. Krier, R. S. Schwartz, C. Napoli, and J. C. Romero Increased Oxidative Stress in Experimental Renovascular Hypertension Hypertension, February 1, 2001; 37(2): 541 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Touyz and E. L. Schiffrin Signal Transduction Mechanisms Mediating the Physiological and Pathophysiological Actions of Angiotensin II in Vascular Smooth Muscle Cells Pharmacol. Rev., December 1, 2000; 52(4): 639 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Prasad, T. Tupas-Habib, W. H. Schenke, R. Mincemoyer, J. A. Panza, M. A. Waclawin, S. Ellahham, and A. A. Quyyumi Acute and Chronic Angiotensin-1 Receptor Antagonism Reverses Endothelial Dysfunction in Atherosclerosis Circulation, May 23, 2000; 101(20): 2349 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dimmeler, V. Rippmann, U. Weiland, J. Haendeler, and A. M. Zeiher Angiotensin II Induces Apoptosis of Human Endothelial Cells : Protective Effect of Nitric Oxide Circ. Res., December 19, 1997; 81(6): 970 - 976. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||